317 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
CLNX | €33.92 | 7.5% | -3.2% | €23.6b | €44.11 | PS6x | E72.8% | 0.2% | Telecom | ||
ILMN | US$144.36 | 9.6% | 42.1% | US$22.7b | US$164.60 | PS5.2x | E70.4% | 2.2% | Pharmaceuticals & Biotech | ||
000002 | CN¥8.48 | -2.3% | -25.9% | CN¥94.6b | CN¥7.35 | PS0.3x | E99.0% | 0% | Real Estate Management and Development | ||
ADE | NOK 114.20 | 0.4% | 41.5% | NOK 139.1b | NOK 113.94 | PS6.5x | E83.0% | n/a | Media | ||
APG New | US$37.55 | 4.3% | 24.1% | US$10.3b | US$43.33 | PS1.5x | E87.9% | n/a | Capital Goods | ||
A035720 | ₩38,200.00 | 8.7% | -24.4% | ₩16.8t | ₩47,546.67 | PS2.1x | E66.9% | 0.2% | Media | ||
1COV | €57.58 | 0.9% | 19.5% | €10.8b | €60.92 | PS0.8x | E62.2% | 0% | Materials | ||
GALD | CHF 89.75 | 5.4% | n/a | CHF 21.1b | CHF 93.19 | PS5.6x | E44.4% | n/a | Pharmaceuticals & Biotech | ||
LPLA | US$325.72 | 2.7% | 50.2% | US$24.5b | US$312.07 | PE24.3x | E13.5% | 0.4% | Diversified Financials | ||
4755 | JP¥854.70 | -4.2% | 45.9% | JP¥1.8t | JP¥969.33 | PS0.8x | E81.9% | 0% | Retail | ||
2002 | NT$21.75 | -1.4% | -17.0% | NT$331.7b | NT$24.07 | PE84.9x | E60.3% | 1.6% | Materials | ||
DSFIR | €103.75 | -1.0% | 19.4% | €27.7b | €128.96 | PS2.2x | E43.6% | 0.9% | Materials | ||
UN0 | €44.40 | 5.2% | -42.9% | €17.4b | €35.83 | PS0.2x | E64.7% | 0% | Utilities | ||
GMED | US$85.29 | 2.0% | 90.3% | US$11.5b | US$90.54 | PE126.9x | E49.0% | n/a | Healthcare | ||
CIEN New | US$69.17 | 4.0% | 52.7% | US$10.2b | US$65.73 | PE72.3x | E39.5% | n/a | Tech | ||
PHIA | €25.85 | 3.3% | 42.4% | €24.1b | €28.72 | PS1.3x | E60.9% | n/a | Healthcare | ||
ALO | €20.94 | 0.2% | 84.2% | €9.5b | €22.93 | PS0.5x | E58.2% | 0% | Capital Goods | ||
TWLO | US$102.91 | 4.5% | 55.6% | US$16.0b | US$86.74 | PS3.6x | E86.6% | n/a | Software | ||
COHR | US$98.09 | -5.1% | 163.3% | US$15.6b | US$109.50 | PS3x | E110.2% | n/a | Tech | ||
UCB | €182.45 | 4.8% | 168.9% | €35.1b | €179.83 | PE144.2x | E35.9% | 0.7% | Pharmaceuticals & Biotech | ||
6502 | JP¥4,590.00 | 0% | 5.2% | JP¥2.0t | JP¥4,606.67 | PS0.6x | E81.9% | 0% | Capital Goods | ||
KRTX | US$329.83 | 3.3% | 80.7% | US$12.6b | US$326.92 | PS19238.9x | E60.1% | n/a | Pharmaceuticals & Biotech | ||
FND | US$114.08 | 10.2% | 23.7% | US$12.3b | US$104.04 | PE62.6x | E17.6% | n/a | Retail | ||
VRTX | US$464.56 | 3.0% | 32.4% | US$120.3b | US$514.81 | PS11.3x | E47.4% | n/a | Pharmaceuticals & Biotech |